Form 4: Immunome CFO Max Rosett Granted 207,000 Stock Options

Immunome Inc.'s Chief Financial Officer, Max Rosett, was granted 207,000 employee stock options with an exercise price of $10.60 per share.

Summary

• Immunome Inc. granted 207,000 employee stock options to its Chief Financial Officer, Max Rosett.
• The options have an exercise price of $10.60 per share.
• The transaction date for the option grant was July 29, 2025.
• The options will vest with 25% of the shares on July 29, 2026, and then 1/36th of the remaining shares will vest monthly thereafter.
• The options have an expiration date of July 28, 2035.
• Following this transaction, Max Rosett beneficially owns 207,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects standard executive incentive alignment and retention, without indicating any negative operational or financial news.

Positives

• The grant of stock options aligns the Chief Financial Officer's incentives with the long-term performance and shareholder value of Immunome Inc.
• This compensation structure can aid in the retention of key executive talent.

Negatives

• The exercise of these options in the future could lead to a minor dilutive effect on existing shareholders, although this is a standard characteristic of stock option grants.

Future Outlook

The options are structured with a vesting schedule extending over several years, indicating a long-term incentive for the Chief Financial Officer, with the first significant vesting occurring on July 29, 2026, and monthly vesting thereafter until the options are fully vested or expire.

Industry Context

The granting of stock options to key executives like the Chief Financial Officer is a common practice in the biotechnology and pharmaceutical industries, serving as a standard component of executive compensation packages designed to attract, retain, and incentivize leadership.

Comparison to Industry Standards

• The grant of stock options to a Chief Financial Officer is a common and widely accepted practice for executive compensation across various industries, including biotechnology.
• While specific comparable companies or projects are not detailed in this filing, such grants are typically benchmarked against peer companies of similar size and stage of development to ensure competitive compensation and alignment with market practices.

Related Party Transactions

• The grant of 207,000 employee stock options to Max Rosett, the Chief Financial Officer, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from improved executive incentive alignment.
• Employees: No direct impact on general employees, but reinforces the company's approach to executive compensation.
• Management (CFO): Directly benefits from the potential for future equity gains, aligning personal financial interests with company performance.

Next Steps

• The options will begin vesting on July 29, 2026, with 25% of the shares.
• Monthly vesting of 1/36th of the remaining shares will occur thereafter.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (stock option grant) and does not contain information significant enough to alter a fundamental investment thesis. It is a standard practice for incentivizing management and does not reflect new operational performance, strategic shifts, or financial results that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide a basis for a 'buy' or 'sell' decision.

Keywords

Immunome Inc., IMNM, Stock Options, Executive Compensation, CFO, Max Rosett, SEC Form 4, Insider Transaction, Equity Grant, Vesting Schedule